Monoclonal gammopathy of undetermined significance:: Predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size

被引:60
作者
Rosinol, Laura
Cebeira, M. Teresa
Montoto, Silvia
Rozman, Maria
Esteve, Jordi
Filella, Xavier
Blade, Joan
机构
[1] Univ Barcelona, Hosp Clin Barcelona, Dept Hematol, E-08036 Barcelona, Spain
[2] Univ Barcelona, Hosp Clin Barcelona, Hematopathol Dept, E-08036 Barcelona, Spain
[3] Univ Barcelona, Hosp Clin Barcelona, Dept Biochem, E-08036 Barcelona, Spain
[4] Univ Barcelona, Hosp Clin Barcelona, IDIBAPS, Inst Hematol & Oncol, E-08036 Barcelona, Spain
关键词
D O I
10.4065/82.4.428
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: To investigate the predictors of monoclonal gammopathy of undetermined significance (MGUS) by considering not only the initial features but also the pattern of evolution of the M protein during the first years after diagnosis. PATIENTS AND METHODS: This study consisted of 359 patients diagnosed as having MGUS at a single institution. Patients who showed a definite and progressive increase in their M protein size according to serum electrophoresis during the first 3 years of follow-up were considered to have evolving MGUS, whereas all others were considered to have nonevolving MGUS. RESULTS: Of the 359 patients, 330 had nonevolving MGUS, whereas 29 fulfilled the criteria for evolving MGUS. Overall, 32 patients developed malignant transformation. The progression rates at 10 and 20 years of follow-up for the evolving and the nonevolving types were 55% vs 3.0% and 80% vs 13%, respectively. Multivariate analysis revealed that the features significantly associated with a higher risk of progression were evolving MGUS (relative risk [RR], 12.3.4;. P<.001), IgA MGUS (RR, 2.93; P=.006), and M protein concentration (RR, 2.18; P=.04). CONCLUSION: The evolutionary pattern of serum M protein (progressive increasing vs stable) during the first years of follow-up is the most important risk factor for disease progression in patients with MGUS.
引用
收藏
页码:428 / 434
页数:7
相关论文
共 16 条
[1]   Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy [J].
Baldini, L ;
Guffanti, A ;
Cesana, BM ;
Colombi, M ;
Chiorboli, O ;
Damilano, I ;
Maiolo, AT .
BLOOD, 1996, 87 (03) :912-918
[2]   MALIGNANT TRANSFORMATION AND LIFE EXPECTANCY IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE [J].
BLADE, J ;
LOPEZGUILLERMO, A ;
ROZMAN, C ;
CERVANTES, F ;
SALGADO, C ;
AGUILAR, JL ;
VIVESCORRONS, JL ;
MONTSERRAT, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1992, 81 (03) :391-394
[3]   Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma [J].
Cesana, C ;
Klersy, C ;
Barbarano, L ;
Nosari, AM ;
Crugnola, M ;
Pungolino, E ;
Gargantini, L ;
Granata, S ;
Valentini, M ;
Morra, E .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1625-1634
[4]  
COX DR, 1972, J R STAT SOC B, V34, P187
[5]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[7]   A long-term study of prognosis in monoclonal gammopathy of undetermined significance [J].
Kyle, RA ;
Therneau, TM ;
Rajkumar, SV ;
Offord, JR ;
Larson, DR ;
Plevak, MF ;
Melton, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (08) :564-569
[8]   Long-term follow-up of 241 patients with monoclonal Gammopathy of undetermined significance: The original Mayo clinic series 25 years later [J].
Kyle, RA ;
Therneau, TM ;
Rajkumar, SV ;
Larson, DR ;
Plevak, MF ;
Melton, LJ .
MAYO CLINIC PROCEEDINGS, 2004, 79 (07) :859-866
[9]   Prevalence of monoclonal gammopathy of undetermined significance [J].
Kyle, RA ;
Therneau, TM ;
Rajkumar, SV ;
Larson, DR ;
Plevak, MF ;
Offord, JR ;
Dispenzieri, A ;
Katzmann, JA ;
Melton, LJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (13) :1362-1369
[10]   SMOLDERING MULTIPLE-MYELOMA [J].
KYLE, RA ;
GREIPP, PR .
NEW ENGLAND JOURNAL OF MEDICINE, 1980, 302 (24) :1347-1349